Pulmonary disease, chronic obstructive Trials in Killeen, United States
Conditions / Pulmonary disease, chronic obstructive / Killeen, United States
Research into Pulmonary disease, chronic obstructive spans multiple therapeutic approaches and trial phases.
16 total trials for this combination
Showing top 10 of 16 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00400153 | Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | PHASE3 |
| NCT01431287 | Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | PHASE3 |
| NCT00662740 | Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD) | TERMINATED | PHASE3 |
| NCT00387088 | Tiotropium / Respimat One Year Study in COPD. | COMPLETED | PHASE3 |
| NCT01964352 | Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1) | COMPLETED | PHASE3 |
| NCT01313676 | Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease | COMPLETED | PHASE3 |
| NCT00528996 | An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler. | COMPLETED | PHASE2 |
| NCT01694771 | Co-administration of Olodaterol Respimat® and Tiotropium Handihaler® | COMPLETED | PHASE3 |
| NCT02296138 | Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease. | COMPLETED | PHASE3 |
| NCT01019694 | Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease | COMPLETED | PHASE3 |